Compare ANAB & VMET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANAB | VMET |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2015 | N/A |
| Metric | ANAB | VMET |
|---|---|---|
| Price | $62.02 | $11.23 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $74.64 | N/A |
| AVG Volume (30 Days) | ★ 601.6K | 209.8K |
| Earning Date | 05-04-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $185.73 |
| Revenue Next Year | $31.11 | $6.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $15.40 | $9.10 |
| 52 Week High | $68.39 | $11.79 |
| Indicator | ANAB | VMET |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 51.45 |
| Support Level | $43.67 | $9.14 |
| Resistance Level | $67.69 | N/A |
| Average True Range (ATR) | 4.07 | 0.60 |
| MACD | -0.57 | 0.11 |
| Stochastic Oscillator | 60.16 | 97.76 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).